JP Morgan Chase’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$178M Sell
200,400
-25,100
-11% -$25.4M 0.01% 738
2025
Q4
$242M Buy
225,500
+115,700
+105% +$111M 0.02% 605
2025
Q3
$83.8M Sell
109,800
-55,200
-33% -$41.1M 0.01% 1085
2025
Q2
$129M Sell
165,000
-217,500
-57% -$169M 0.01% 827
2025
Q1
$316M Sell
382,500
-44,000
-10% -$36.6M 0.02% 521
2024
Q4
$329M Buy
426,500
+66,700
+19% +$55.2M 0.02% 499
2024
Q3
$319M Buy
359,800
+114,900
+47% +$103M 0.02% 515
2024
Q2
$222M Sell
244,900
-51,600
-17% -$41.3M 0.02% 625
2024
Q1
$231M Buy
296,500
+25,900
+10% +$18.4M 0.02% 608
2023
Q4
$158M Buy
270,600
+12,700
+5% +$7.41M 0.02% 697
2023
Q3
$139M Buy
257,900
+119,500
+86% +$61.6M 0.02% 674
2023
Q2
$64.9M Buy
138,400
+55,300
+67% +$23.2M 0.01% 1008
2023
Q1
$28.5M Sell
83,100
-28,900
-26% -$9.75M ﹤0.01% 1401
2022
Q4
$41M Sell
112,000
-57,600
-34% -$20.4M 0.01% 1213
2022
Q3
$54.8M Sell
169,600
-41,800
-20% -$13.2M 0.01% 1010
2022
Q2
$68.5M Sell
211,400
-6,900
-3% -$2.07M 0.01% 904
2022
Q1
$62.5M Sell
218,300
-68,500
-24% -$17.6M 0.01% 1056
2021
Q4
$79.2M Buy
286,800
+65,300
+29% +$16.6M 0.01% 988
2021
Q3
$51.2M Buy
221,500
+122,900
+125% +$30.3M 0.01% 1167
2021
Q2
$22.6M Buy
98,600
+21,200
+27% +$4.26M ﹤0.01% 1730
2021
Q1
$14.5M Buy
77,400
+77,000
+19,250% +$15.1M ﹤0.01% 2019
2020
Q4
$68K Sell
400
-430,000
-100% -$64.2M ﹤0.01% 5086
2020
Q3
$63M Buy
430,400
+429,300
+39,027% +$66.4M 0.01% 867
2020
Q2
$181K Sell
1,100
-99,600
-99% -$15.3M ﹤0.01% 4311
2020
Q1
$14M Buy
100,700
+18,000
+22% +$2.47M ﹤0.01% 1481
2019
Q4
$10.9M Sell
82,700
-39,300
-32% -$4.56M ﹤0.01% 2049
2019
Q3
$13.6M Hold
122,000
﹤0.01% 1884
2019
Q2
$13.6M Sell
122,000
-72,800
-37% -$8.57M ﹤0.01% 1861
2019
Q1
$25.3M Sell
194,800
-190,000
-49% -$23.1M 0.01% 1386
2018
Q4
$44.5M Buy
384,800
+68,000
+21% +$7.6M 0.01% 955
2018
Q3
$34M Buy
316,800
+37,800
+14% +$3.78M 0.01% 1263
2018
Q2
$23.8M Buy
279,000
+89,900
+48% +$7.38M ﹤0.01% 1449
2018
Q1
$14.6M Buy
189,100
+57,500
+44% +$4.63M ﹤0.01% 1748
2017
Q4
$11.1M Buy
131,600
+40,000
+44% +$3.4M ﹤0.01% 2037
2017
Q3
$7.79M Buy
91,600
+88,000
+2,444% +$7.22M ﹤0.01% 2193
2017
Q2
$296K Sell
3,600
-247
-6% -$20.2K ﹤0.01% 3890
2017
Q1
$324K Sell
3,847
-112,800
-97% -$9.03M ﹤0.01% 3878
2016
Q4
$8.58M Buy
116,647
+71,647
+159% +$5.34M ﹤0.01% 2032
2016
Q3
$3.61M Buy
+45,000
New +$3.6M ﹤0.01% 2450
2016
Q1
Sell
-70,000
Closed -$5.9M 4819
2015
Q4
$5.9M Hold
70,000
﹤0.01% 2117
2015
Q3
$5.86M Buy
+70,000
New +$5.91M ﹤0.01% 2120
2015
Q1
Sell
-775,146
Closed -$53.5M 4183
2014
Q4
$53.5M Buy
775,146
+754,746
+3,700% +$50.9M 0.01% 894
2014
Q3
$1.32M Buy
+20,400
New +$1.29M ﹤0.01% 3171
2014
Q1
Sell
-10,100
Closed -$515K 3770
2013
Q4
$515K Sell
10,100
-15,500
-61% -$776K ﹤0.01% 3477
2013
Q3
$1.29M Sell
25,600
-6,400
-20% -$335K ﹤0.01% 3109
2013
Q2
$1.57M Buy
+32,000
New +$1.74M ﹤0.01% 2962

Other funds holding LLY

JP Morgan Chase's LLY Position: Q1 2026 in Review

JP Morgan Chase increased its Eli Lilly (LLY) stake by 5.4% in Q1 2026, buying an estimated $710M and bringing the position to 13,698,491 shares worth $12.1B. The position accounts for 0.78% of the portfolio, ranked #18.

JP Morgan Chase first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $17.1B in Q2 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • JP Morgan Chase held 13,698,491 shares of Eli Lilly worth $12.1B as of Q1 2026.
  • JP Morgan Chase bought 700,545 Eli Lilly shares in Q1 2026, an estimated $710M.
  • Eli Lilly made up 0.78% of JP Morgan Chase's portfolio in Q1 2026, its #18 holding.
  • JP Morgan Chase first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's Eli Lilly position peaked at $17.1B in Q2 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.